STOCKS NEWS EUROPE-Ablynx soars on positive trial result

key test. Ablynx said after the market closed on Tuesday that its rheumatoid arthritis drug, ATN-103, licensed to Pfizer (PFE.N: Quote, Profile, Research), met its goals in a mid-stage, Phase II test. "It's the first time that a molecule of that platform...